## REFERENCES

Allémann, E., Doelker, E., Gurny, R. 1993. Drug loaded poly (lactic acid) nanoparticles produced by a reversible salting-out process: purification of an injectable dosage form. Eur. J. Pharm. Biopham. 39:13-18.

Allémann, E., Gurny, R., Leroux, J. C. 1996. Biodegradable nanoparticles of poly (lactic acid) and poly (lactic-co-glycolic acid) for parenteral administration. In Lieberman, H. A., Rieger, M. M., Banker, G. S. (eds.), Pharmaceutical Dosage Forms: Disperse Systems, pp. 163-194. New York: Marcel Dekker.

Bhushan, B. 2004. Introduction to Nanotechnology. In Springer Handbook of Nanotechnology, pp. 1-6, New York: Springer.
Bidlack, W. R., Omaye, S. T., Meskin, M. S., Jahner, D. 1998. Phytochemicals: A new paradigm. Lancaster:Technomic Publishing Co., Inc.
Bonte, F., Noel-Hudson, M. S., Wepierre, J., Meybeck, A. 1997. Protective Effect of Curcuminoids on Epidermal Skin Cells under Free Oxygen Radical Stress Planta Med. 63: 265-266.

Bodmeier, R., Maincent, Ph. 1996. Polymeric Dispersion as Drug Carrier. In Lieberman, H. A., Rieger, M. M., Banker, G. S. (eds.), Pharmaceutical Dosage Forms: Disperse Systems, pp. 87-126. New York: Mercel Dekker.

Bogunia-Kubik, K., Sugisaka, M. 2002. From molecular biology to nanotechnology and nanomedicine. Biosystem 65: 123-138.

Box, G. E. P., Draper, N. R. 1986. Empirical model-building and response surfaces. New York: John Wiley and sons.

Box, G. E. P., Hunter, W. G., Hunter, J. S. 1978. Statistics for experimenters : an introduction to design. data analvsis, and model building. New York: John Wiley \& Sons.

Brophy, M. R., Deasy, P. B. 1990. Biodegradable Polyester Polymers as Drug Carriers. In Awarbrick, J., Boylan, J. C. (ed.), Encyclopedia of Pharmaceutical Technology, pp. 1-25. New York: Marcel Dekker.

Brouet, I., Oshima, H. 1995. Curcumin, an anti-tumour promoter and antiinflammatory agent, inhibits induction of nitric oxide synthase in activated macrophages. Biochem. Biophys. Res. Commun. 206(2):533-540.
Cauchetier, E., Deniau, M., Fessi, H., Astier, A., Paul, M. 2003. Atovaquone-loaded nanocapsules: influence of the nature of the polymer on their in vitro characteristics. Int.J. Pharm. 250: 273-281.

Chuang, S., Cheng, A., Lin, J., Kuo, M. 2000. Inhibition by curcumin of Diethylnitrosamine - induced hepatic hyperplasia, inflammation, cellular gene products and cell-cycle-related proteins in rats. Food Chem. Toxicol. 38:991995.

Das, C. K., Das, K. C. 2002. Curcumin (diferuloylmethane), a singlet oxygen quencher. Biochem. Biophys. Res. Comm. 295: 62-66.

Davda, J., Labhastwar, V. 2002. Characterization of nanoparticle uptake by endothelial cells. Int. J. Pharm. 233: 51-59.
de Campos, A. M., Sánchez, A., Alonso, M. J. 2001. Chitosan nanoparticles: a new vehicle for the improvement of the delivery of drugs to the ocular surface, application to cyclosporin A. Int. J. Pharm. 224: 159-168.
de la Maza, A., Manich, A. M., Coderch, L., Bosch, P., Parra, J.L. 1995. The formation of liposomes in vitro by mixtures of lipids modeling the composition of the stratum corneum. Colloids and Surfaces A: Phys-Chem. Eng. Aspects 101:9-19.

Dingler, A., Blum. R. P., Niehus, H., Muller, R. H., Gohla, S. 1999. Solid lipid nanoparticles (SLN/Lipopearls)-a pharmaceutical and cosmetic carrier for the application of vitamin E in dermal products. J. Microencapsul. 16: 751-767.

Fonseca, C., Simões, S., Gaspar, R., 2002. Paclitaxel-loaded PLGA nanoparticles: preparation, physicochemical characterization and in vitro anti-tumoral activity. J. Control. Rel. 83: 273-286.

Govender, T., Stolnik, S., Garnette, M. C., Illum, L., Davis, S. 1999. PLGA nanoparticles prepared by nanoprecipitation:drug loading and release studies of water soluble drug. J. Control. Rel. 57: 171-185.

Grinberg, L. N., Shalev, O., Tønnesen, H. H., Rachmilewitz, E. A. 1996. Studies on curcumin and curcuminoids: XXVI Antioxidant effects of curcumin on the red blood cell membrane. Int. J. Pharm. 132: 251-257.

Heng, M. C., Song, M. K., Harker, J., Heng, M. K. 2000. Drug-induced Suppression of phosphorylase kinase activity correlates with resolution of psoriasis as assessed by clinical, histological and immunohistochemical parameters. Br. J. Dermatol. 143: 937-949.

Huang, M-T., Ma, W., Yen, P., Xie, J-G., Han, J., Frenkel, K., Grunberger, D., Conney, A. H. 1997. Inhibitory effects of topical-application of low doses of curcumin on 12-O- tetradecanoylphorbol-13-acctate-induced tumor promotion and oxidized DNA bases in mouse epidermis. Carcinogenesis 18(1): 83-88.
Ibrahim, H., Bindschaedler, C., Doelker, E., Buri, P., Gurny, R. 1992. Aqueous nanodispersions prepared by a salting-out process. Int. J. Pharm. 87: 239-246.

Illum, L., Jabbal-Gill, I, Hinchcliffe, M., Fisher, A. N., Davis, S. S. 2001. Chitosan a novel nasal delivery system for vaccines. Adv. Drug. Deliv. Rev. 51: 81-96.

Inano, H., Oncda, M., Inafuku, N., Kubota, M., Kamada, Y., Osawa, T., Kobayashi H., Wakabayashi, K. 2000. Potent preventive action of curcumin on radiationinduced intiation of mammary tumorigenesis in rats. Carcinogenesis 21: 18351841.

Ireson, C. R., Orr, S., Jones, D. J. D., Verschoyle, R., Lin, C. K., Williams, M., Howwlis, L., Plummer, S., Jukes, R., Steward, W. P., Gescher, A. J. 2001. Identification of metabolites of the chemopreventive agent curcumin in human and rat hepatocytes and in the rat in vivo and evaluation of their ability to inhibit phorbol ester-induced prostaglandin E-2 priduction. Cancer Res . 61: 1058-1064.

Jayadeep, V. R., Arun, O. S., Sudhakaran P. R., Menon, V. P., 2000. Changes in the prostaglandin levels in alcohol toxicity: effect of curcumin and N acetylcysteine. J. Nutr. Biochem. 11: 509-514.

Jayaprakasha, G. K., Rao, L. J. M., Sakariah, K. K. 2002. Improved HPLC Method for the Determination of Curcumin, Demethoxycurcumin and Bisdemethoxycurcumin. J. Agric. Food Chem. 50: 3668-3672.

Jain, R. A. 2000. The manufacturing techniques of various drug loaded biodegradable Poly (lactide-co-glycolide) (PLGA) devices. Biomaterials 21: 2475-2490.

Jenning, V., Gysler, A., Schafer-Korting, M., Gohla, S. H. 2000. Vitamin A loaded solid lipid nanoparticles for topical use: occlusive properties and drug targeting to the upper skin. Eur. J. Pharm. Biopharm. 49: 208-211.

Joe, B., Lokesh, B. R. 1997. Prophylactic and therapeutic effects of n-3 polyunsaturated fatty acids, capsaicin, and curcumin on adjuvant arthritis in rats. J. Nutr. Biochem. 8: 397-407.

Karnachi, A. A., Khan, M. A. 1996. Box-Behnken design for the optimization of formulation variables of indomethacin coprecipitates with polymer mixtures. Int. J. Pharm. 131: 9-17.

Khafif, A., Schantz, S. P., Chou, T. C., Elderstein, D., Sacks, P. G. 1998. Quantitation of chemopreventive synergism between ( $(-)$ - epigallocatechin-3-gallate and curcumin in normal, premalignant and malignant human oral epitheriai cells. Carcinogenesis 19 (3): 419-424.

Krause, H. J., Sehwarz, A., and Rohdewald, P. 1985. Polylactic acid nanoparticles, a colloidal drug delivery system for lipophilic drugs. Int. J. Pharm. 27: 145-155.

Kreuter, J. 1988. Nanoparticles. In Swarbrick, J., Boylan, J. C., (eds.), Encyclopedia of Pharmaceutical Technology, Vol.10, pp.165-190. New York: Marcel Dekker.

Kreuter, J. 1994. Nanoparticles. In Kreuter, J. (ed.), Colloidal Drug Delivery System, pp. 219-342. New York: Marcel Dekker.

Kreuter, J. 2001. Nanoparticulate systems for brain delivery of drugs. Adv. Drug. Deliv. Rev. 47: 65-81.

Lemoine, D., Francois, C., Kedzierewicz, F., Preat, V., Hoffman, M., Maincent, P. 1996. Stability study of nanoparticles of poly (DL-lactide-co-glycolide). Biomaterials 17: 2191-2197.

Limtrakul, P., Lipigorngoson, S., Namworng, O., Apisariyakul, A.,Dunn, F. W. 1997. Inhibitory effect of dietary curcumin on skin carcinogenesis in mice. Cancer Letter 116: 197-203.

Literat, A., Su, F., Norwicki, M., Durand, M.,Ramanathan, R., Jones, C. A., Minoo, P., Kwong, K. Y. 2001. Regulation of pro-inflammatory cytokine expression by curcumin in hyaline membrane disease (H: 亻D). Life Sciences 70: 253-267.
Montgomery, D. C. 2001. Design and Analysis of Experiments. $5{ }^{\text {th }} \mathrm{ed}$. New York: John Wiley \& Sons.
Mu, L., Feng, S. S. 2002. Vitamin E TPGS used as emulsifier in the solvent evapolation/extraction technique for fabrication of polymeric nanospheres for controlled release of paclitaxel (Taxol®). J. Control. Rel. 80: 129-144.
Murakami, H.,Kobayashi, M., Takeuchi, H., Kawashima, Y. 1999. Preparation of poly (DL-lactide-co-glycolide) nanoparticles by modification solvent diffusion method. Int. J. Pham. 187: 143-152.
Murakami, H.,Kobayashi, M., Takeuchi, H., Kawashima, Y. 2000. Further application of a modified spontaneous emulsification solvent diffusion method to various types of PLGA and PLA polymers for preparation of nanoparticles. Powder Technology 107:137-143.

Nazzal, S., Nutan, M., Palamakula, A., Shah, R., Zaghloul, A. A., Khan, M. A. 2002. Optimization of a self-nanoemulsified tablet dosage form of Ubiquinone using response surface methodology : effect of formulation ingredients. Int. J. Pharm. 240: 103-114.

Niwa, T., Takeuchi, H., Hino, Y., Kunou, N., Kawashima, Y . 1993. Preparations of biodegradable nanospheres of water-soluble and insoluble drugs with d, llactide/glycolide copolymer by a novel spontaneous emulsification solvent diffusion method, and the drug release behavior. J. Control. Rel. 25: 89-98.

Panyam, J., Labhasetwar, V. 2003. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Advance Drug Delivery Reviews 55: 329-347.

Perkins, S., Verschoyle, R. D., Hill, K., Parveen, I., Threadgill, M. D., Sharma, R. A., Williams, M. L., Steward, W. P., Gescher, A. J. 2002. Chemopreventive efficacy and pharmacokinetics of curcumin in the Min/+ Mouse, a model of familial adenomatous polyposis. Cancer Epidemiology, Biomarkers and Prevention 11: 535-540.

Perugini, P., Simeoni, S., Scalia, S., Genta, I., Modena, T., Conti, B., Pavanetto, F. 200-. Effect of nanoparticle encapsulation on the photostability of the sunscreen agent, 2- Ethylhexyl-p-methoxycinnamate. Int. J. Pharm. 246: 37-45.

Pinto-Alphandary, H., Andremont, A., Couvreur, P. 2000. Targeted delivery of antibiotics using liposomes and nanoparticles: research and applications. Int. J. Antimicrobial Agents 13: 155-168.

Pirker, S., Kruse, J., Noe, C., Langer, K., Zimmer, A., Kreuter, J. 1996. Characterization of polybutycyanoacrylate nanoparticles. Part II: Determination of polymer content by NMR-analysis. Int. J. Pharm. 128: 189-195.
Ragonese, R., Macka, M., Hughes, J., Petocz, P. 2002. The use of the Box-Behnken experimental design in the optimisation and robustness testing of a capillary electrophoresis method for the analysis of ethambutol hydrochloride in a pharmaceutical formulation. J. Pharn. Biomed. Anal. 27: 995-1007.

Ramírez-Tortosa, M. C., Mesa, M. D., Aguilera, M. C., Quiles, J. L., Baró, L., Ramírez-Tortosa, C.L., Martinez-Victoria, E., Gil, A. 1999. Oral administration of a turmeric extract inhibits LDL oxidation and has hypocholesterolemic effects in rabbits with experimental atherosclerosis. Atherosclerosis 147: 371378.

Russell-Jones, G. J., Arthur, L., Walker, H. 1999. Vitamin B 12 -medialed transport of nanoparticles across CaCo-2 cells. Int. J. Pharm. 179: 247-255.

Sastry, S. V., Reddy, I. K., Kham, M. A. 1997. Atenolol gastrointestinal therapeutic system: optimization of formulation variables using response surface methodology. J. Control. Rel. 45: 121-130.

Santos-Magalhães, N. S., Pontes, A., Pereira, V. M. W., Caetano, M. N. P. 2000. Colloidal carriers for benzathine penicillin G : Nanoemulsions and nanocapsules. Int. J. Pharm. 208: 71-80.
Saxena, V., Sadoqui, M., Shao, J. 2004. Enhanced photo-stability and aqueousstability of indocyanine green in polymeric nanoparticulate systems. J. Photochem. Photobiol. B: Biol. 74: 29-38.

Saxena, V., Sadoqui, M., Shao, J. 2004. Indocyanine green - loaded biodegradable nanoparticles: preparation, physicochemical characterization and in vitro release. Int. J. Pharm. 278: 293-301.

Schroeder, U., Sommerfeld, P., Ulrich, S., Sabel, B. A. 1998. Nanoparticle technology for delivery of drugs across the blood-brain barrier. J. Pharm. Sci. 87: 13051307.

Sharma, A., Sharma, U. S. 1997. Liposomes in drug delivery: progress and limitations. Int. J. Pharm 154: 123-140.

Sharma, R. A., McLelland, H. R., Hill, K. A., Ireson, C. R., Euden, S. A., Manson, M. M., Pirrnohamed, M., Marnett, L. J., Gescher A. J., Steward, W. P. 2001. Pharmacodynamic and pharmacokinetic study of oral Curcuma extract in patients with colorectal cancer. Clin. Cancer Res. 7: 1984-1900.
Sila, G. A. 2004. Introduction to nanotechnology and its applications to medicine. Surg. Neurol. 61: 216-220.

Smith, A.T. 1998. Comparison of information - yield from different experimental designs used in algal toxicity testing of chemical mixtures. Environmental Pollution 102: 205-212.

Song, C. X., Labhasetwar, V., Murphy, H., Qu, X., Humphrey, W. R., Shebuski, R. J., Levy, R. J. 1997. Formulation and characterization of biodegradable nanoparticles for intravascular local drug delivery. J. Control.Rel. 43: 197-212.
Song, E. K., Cho, H., Kim, J. S., Kim, N. Y., An, N. H., Kim, J. A., Lee, S. H., Kim, Y. C. 2001. Diarylheptanoids with Free Radical Scavenging and Hepatoprotective Activity in vitro from Curcuma longa. Planta Med. 67: 876877.

Soppimath, K. S., Aminabhavi, M. T., Kulkarni, A. R., Rudzinski, W. E. 2001. Biodegradable polymeric nanoparticles as drug delivery devices. J. Control. Rel. 70:1-20.

Thai Herbal Pharmacopoeia Volume I, 1995. pp. 38-44,84.
Thombre, A. G., Cardinal, J. R. 1988. Biopolymers for Controlied Drug Delivery. In Swarbrick, J., Boylan, J. C. (eds.), Encyclopedia of Pharmaceutical Technology, Vol. 2, p.p. 61-88. , New York: Marcel Dekker.

Tønnesen, H. H., Grinberg, L. N., Shalev, O., Rachmilewitz, E. A. 2002. Studies of curcumin and curcuminoids: Cyclodextrin complexation: solubility, chemical and photochemical stability. Int. J. Pharm. 244: 127-135.

Vandevoort, J., Ludwig, A. 2002. Biocompatible stabilizers in the preparation of PLGA nanoparticles: a factorial design study. Int. J. Pharm: 23: 77-92.

Wang, Y. J., Pan, M. H., Cheng, A. L., Lin, L. I., Ho, Y. S., Hsieh, C. Y., Lin, J. K. 1997. Stability of curcumin in buffer solutions and Characterization of its degradation products. J. Pharm. Biomed. Anal. 15: 1867-1876.

Zambaux, M. F., Bonneaux, R. G., Maincent, P., Dellacherie, E., Alonso, M. J., Labrude, P., Vigneron, C. 1998. Influence of experimental parameters on the characteristics of poly(lactic acid) nanoparticles prepare by double emulsion method. J. Control. Rel. 50: 31-40.
Zeaiter, M., Roger, J.-M., Bellon-Maurel, V., Ruttledge, V., Rutledge, D. N. 2004. Robustness of models developed by multivariate calibration. Part I: The assessment of robustness. Trends in Analytical Chemistry Vol. 23, No. 2.


Appendices


Appendix A
Detail in Statistic Analysis and Glossary of Terms


จุฬาลงกรณ์มหาวิทยาลัย Chuminomekorn Ilanercity

## Transformation of the Response

Transformation of the response is an important component of any data analysis. Transformation is needed if the error (residuals) is a function of the magnitude of the response (predicted values). Transformations may be needed to meet the assumptions that make the ANOVA valid. Residuals must be normally distributed with a constant variance.

Check the diagnostic plots to validate these assumptions. If the plots don't look right, come back and try some transformations. Extensive diagnostic capabilities to check if the statistical assumptions underlying the data analysis are met. The normal plot of the residuals tests their normality. The residuals versus predicted response values plot will indicate a problem if a pattern exists. Unless the ratio of the maximum response to the minimum response is large, transforming the response will not make much difference.

Here is a list of the transformations and some data types that may benefit from. using that transformation:

Square Root: Count or Frequency data
Natural Log: Variance (std dev) or Growth data
Base 10 Log: Variance (std dev) or Growth data
Inverse Square Root:
Inverse: Rate data, Decay data
Power:
Logit: Bounded data, Yield data
Arcsin Sqr Root: Probability, Fraction defective

The appropriate choice of a response transformation relies on subject matter knowledge and/or statistical considerations.

The power transformation allows transformation to any power in the range -3 to +3 , provided the data are positive. A constant may be added to the data to avoid powers of negative numbers. If the standard deviation associated with an observation is
proportional to the mean raised to some power, then transforming the observation by a power gives a scale satisfying the equal variance requirement of the ANOVA. The Box Cox plot is also provided in the Diagnostics plots that can help to choose an appropriate power transformation.

The logit transformation is useful if the response has a finite range, such as $0 \%$ to $100 \%$. Logit spreads out the values near the boundaries. The actual response data collected must be between the lower and upper limit, and not equal to either one. When using this transformation, it is very important to correctly set the lower and upper limits to the natural limits of the response.

The arcsine square root should be used for binomial data, for example, fraction defective. For this transformation to be valid, the response data must be in terms of fractions between zero and one, from samples of equal size.

Most data transformations can be described by the power function,

$$
\delta=\operatorname{fn}(\mu \alpha)
$$

Where; sigma ( $\delta$ ) is the standard deviation,
$\mathrm{mu}(\mu)$ is the mean
alpha $(\alpha)$ is the power.

Lambda $(\lambda)$ is $1-\alpha$ in all cases. If the standard deviation associated with an observation is proportional to the mean raised to the $\alpha$ power, then transforming the observation by the $1-\alpha$ (or $\lambda$ ) power gives a scale satisfying the equal variance requirement of the statistical model.

As a reminder, here are the commonly used transformations:
$\lambda=-1$ inverse
$\lambda=0$ natural $\log$
$\lambda=0.5$ square root
$\lambda=1$ no transformation

The lowest point on the Box Cox plot represents the value of lambda ( $\lambda$ ) that results in the minimum residual sum of squares in the transformed model. The potential for improvement is greatest when the range of the maximum to minimum response value is greater than 3 .

Power law transformations can only be performed on responses that are greater than zero, so a constant, k , may be needed to add to all the responses.

## Fit Summary

Fit summary shows the statistical tables that can be used to identify which model to choose for in-depth study. It composed of the regression calculations to fit all of the polynomial models to the selected response. The effects for all model terms can be calculated. They can be interpreted line by line as follows:

## Sequential Modei Sum of Squares

Mean: The sum of squares for the effect of the mean.
Blocks: Sequential sum of squares for the effect of blocking (if applicable), after removing the effect of the intercept.

Linear: Sequential sum of squares for the linear terms. The F-value tests the significance of adding linear terms to the intercept and block effects. A small p-value (Prob>F) indicates that adding linear terms has improved the model.

2FI: Sequential sum of squares for the two-factor interaction ( $\mathrm{AB}, \mathrm{BC}$, etc.) terms. The F -value tests the significance of adding interaction terms to the linear model. A small $p$-value ( $\mathrm{Prob}>\mathrm{F}$ ) indicates that adding interaction terms has improved the model.

Quadratic: Sequential sum of squares for the quadratic (A-squared, B-squared, etc.) terms. The F -value tests the significance of adding quadratic terms to the 2FI model. A small p -value (Prob>F) indicates that adding quadratic terms has improved the model.

Cubic: Sequential sum of squares for the cubic terms. The F-value tests the significance of adding cubic terms to the quadratic model. A small p-value (Prob>F) indicates that adding cubic terms has improved the model.

For most response surface methodology (RSM) designs, design points are too small to estimate cubic model. Thus, the cubic model cannot be used.

The column labeled "DF" provides the degrees of freedom for each source. In response surface methodology, the total degrees of freedom equals the number of model coefficients added sequentially line by line.

The model that has p -value ( $\mathrm{Prob}>\mathrm{F}$ ) that is lower than the chosen level of significance (for example 0.05 ) should be selected.

## Lack of Fit

The lack of fit tests that diagnose how well each of the full models fit the data. Models with a significant lack of fit should not be used for predictions.

The F-value compares the variation of the differences in the average responses at the design points, and the corresponding estimated responses using the model, with the expected experimental variation as estimated from replicated design points (Pure Error). It is the mean square for the model lack of fit divided by the mean square for pure error.

The lack of fit tests compare the residual error to the pure error from replicated design points. A lack of fit error significantly larger than the pure error indicates that something remains in the residuals that can be removed by a more appropriate model. If the lack of fit (Prob>F value 0.10 or-smaller), don't use the model as a predictor of the response.

The Lack of Fit statistics will not be obtained if there is no replicate and/or design points are not more unique than model coefficients.

## Model Summary

The "Model Summary Statistics" table lists other statistics used to compare models.

The Std Dev estimates the standard deviation of the error in the design. Smaller is better.

Both the R-Squared and related Adjusted R-Squared statistics should be close to one. A value of 1.0 represents the ideal case at which 100 percent of the variation in the observed values can be explained by the chosen model.

The Predicted R-Squared estimates the amount of variation in new data explained by the model. It can be negative, but this is very bad and suggests that the model consisting of only the intercept is a better predictor of the response than this model. The closer to 1.0 , the better the predicted R -squared.

The PRESS statistic, predicted residual error sum of squares, indicates how wel! the model fits the data. The PRESS for the chosen model should be small relative to the other models under consideration.

R-squared: The multiple correlation coefficient computed as

> 1-SSresidual/(SSmodel + SSresidual)]

An estimate of the fraction of overall variation in the data accounted for by the model. Use the Adjusted R -squared value for designed experiments.

Adjusted R-squared: The R-squared which is adjusted for the number of terms in the model relative to the number of points in the design. An estimate of the fraction of overall variation in the data accounted for by the model.

$$
\begin{aligned}
\text { Adjusted R-squared }= & 1-[(\text { SSresidual } / \text { DFresidual }) /((\text { SSresidual }+ \\
& \text { SSmodel }) /(\mathrm{DF} \text { residual }+ \text { DFmodel }))]
\end{aligned}
$$

Predicted R-squared: Measures the amount of variation in new data explained by the model. Generally, a number closer to one is preferred.

$$
\text { Predicted R-squared = } 1-(\text { PRESS/(SStotal-SSblock }))
$$

PRESS: The Predicted Residual Sum of Squares (PRESS) is a measure of how well the model fits each point in the design. The model is used to estimate each point using all of the design points except that one. The difference between the predicted value and actual value at each point is squared and summed over all of the points. The smaller the PRESS statistic, the better the model fits the data points.

## Model Reduction

The model selected initially contains all of the terms for that polynomial. If there are terms that considered negligible, they can be dropped from the suggested model or added back to the model. Then the statistics for the new selection of terms will be recalculated. Hierarchy of the effects should be retained for making predictions in the actual factor levels.

Model reduction consists of eliminating those terms that are not desired. It can be done manually or automatically. For each response regression, the starting model can be edited by specifying fewer candidate terms than the full model would contain. In the three automatic regression variations you can control those terms which are forced into the model regardless of their entry/exit alpha values.

There are three basic types of automatic model regression:

1. Step-Wise: A term is added, eliminated or exchanged at each step.
2. Backward elimination: A term is eliminated at each step.
3. Forward selection: A term is added at each step.

For well designed experiments (minimal collinearity problems), all three methods should yield the same reduced model.

## Step-Wise Regression

Step-wise regression is a combination of forward and backward regressions. First all blocks and forced terms are fitted to the data. Then begin with a simple regression model using the single term having the highest correlation with the response. After this step, terms are added, eliminated, exchanged, or the procedure stopped.

When two or more terms are in the model:

1. Add to the model the term having the highest partial t -value (or F -value for designs with categorical factors), if it satisfies the alpha-In requirement.
2. Remove all terms (one at a time) having p-values less than the specified alpha-Out. (When categorical factors are in the starting model, terms are added and removed hierarchically.)
3. Stop when there is no further improvement and the alpha-In and alphaOut values are satisfied.

Note that the coefficient shown is the coefficient at the time the term was added or deleted from the model. This is likely to be different than the coefficient that is generated with the completed model. For designs with categorical factors, the coefficients are not shown.

## Backward Elimination

The backward regression procedure differs from stepwise, but the results are often very similar, if not the same. All blocks and forced terms are fit to the data first. Then the remaining candidate factors are considered:

1. Begin with the full model.
2. Remove from the model the term with the highest partial probability value (P-value). For models with categorical factors, terms are removed hierarchically.
3. Stop when the p-value of the next term out satisfies the specified Alpha Out value criterion.

## Forward Selection

When doing forward selection, all blocks and forced terms are fit to the data first. Then the remaining candidate terms are considered:

1. Begin with a simple regression model using the single term having the highest correlation with the response.
2. Add to the model the term with the lowest partial probability value ( P value). For designs with categorical factors, terms are added hierarchically.
3. Stop when the p -value of the next term in does not meet the specified "Alpha In" value criterion.

This algorithm may not be as robust as the others, because some terms may never get the chance to be included in the model. This will only cause concern if the data exhibits a high degree of co-linearity. However, the safest approach may be backward regression.

Note that the coefficient shown is the coefficient at the time the term was added to the model. This is likely to be different than the coefficient that is generated with the completed model. For designs with categorical factors, the coefficients are not shown.

Only blocks and forced terms plus those terms that fail the exit criteria remain. In general, for well-designed experiments with minimal co-linearity, you will see no difference in results. However, the backward method may be the most robust choice since all model terms will be given a chance of inclusion in the model. Conversely, the forward selection procedure starts with a minimal core model, thus some terms never get included.

## ANOVA Output

Model: Terms estimating factor effects.
Sum of Sauares: Total of the sum of squares for the terms in the model, as reported in the Effects List for factorials and on the Model screen for RSM, MIX and Crossed designs.

DF: Degrees of freedom for the model. It is the number of model terms, including the intercept, minus one.

Mean Square: Estimate of the model variance, calculated by the model sum of squares divided by model degrees of freedom.

F Value: Test for comparing model variance with residual (error) variance. If the variances are close to the same, the ratio will be close to one and it is less likely that any of the factors have a significant effect on the response. Calculated by Model Mean Square divided by Residual Mean Square.

Prob > F: Probability of seeing the observed F value if the null hypothesis is true (there is no factor effect). Small probability values call for rejection of the null hypothesis. The probability equals the proportion of the area under the curve of the Fdistribution that lies beyond the observed F value. The F distribution itself is determined by the degrees of freedom associated with the variances being compared. In other words, if the Prob>F value is very small (less than 0.05 ) then the terms in the model have a significant effect on the response.

Term: Each of the listed terms is currently in the model and individual statistics are calculated for them.

Sum of Squares: For factorial terms the sum of squares equation reduces to: the number of factorial experiments divided by 4 times the squared factor effect.

DF: Degrees of freedom for the term. It is the number of levels for the term, minus one.

Mean Square: Estimate of the term variance, calculated by the term sum of squares divided by term degrees of freedom.

F Value: Test for comparing term variance with residual (error) variance. If the variances are close to the same, the ratio will be close to one and it is less likely that the term has a significant effect on the response. Calculated by term Mean Square divided by Residual Mean Square.

Prob > F: Probability of seeing the observed F value if the null hypothesis is true (there is no factor effect). Small probability values call for rejection of the null
hypothesis. The probability equals the proportion of the area under the curve of the F distribution that lies beyond the observed F value. The F distribution itself is determined by the degrees of freedom associated with the variances being compared.

Residual: Consists of terms used to estimate experimental error.
Sum of Squares: This equals the sum of squares for all the terms not included in the model.

DF: The corrected total DF minus the model DF.
Mean Square: The estimate of process variance. The square root of this provides an estimate of the process standard deviation.

Lack of Fit (LOF): This is the variation of the data around the fitted model. If the model does not fit the data well, this will be significant.

Sum of Squares: Residual sum of squares atter removing the pure error sum of squares.

DF: The amount of information available after accounting for blocking, model terms, curvature, and pure error.

Mean Square: Estimate of lack of fit.
F Value: Test for comparing lack of fit variance with pure error variance. If the variances are close to the same, the ratio will be close to one and it is less likely that lack of fit is significant,

Prob>F: Probability of seeing the observed F value if the null hypothesis is true. Small probability values call for rejection of the null hypothesis that lack of fit is not significant. In "plain English", if the Prob>F value is very small (less than 0.05 ) then lack of fit is significant. In other words the variation in the model points significantly differs from the variation in the replicated points. Consider adding more terms to this model. You want the Prob>F value for lack of fit to be greater then 0.10 .

Pure Error: Amount of variation in the response in replicated design points.
Sum of Squares: Pure error sum of squares from replicated points.

DF: The amount of information available from replicated points.
Mean Square: Estimate of pure error variance.

Cor Total: Totals of all information corrected for the mean.
Sum of Squares: Sum of the squared deviations of each point from the mean.
DF: Total degrees of freedom for the experiment, minus one for the mean.

## Summary statistics for the model:

Std Dev: (Root MSE) Square root of the residual mean square. Consider this to be an estimate of the standard deviation associated with the experiment.

Mean: Overall average of all the response data.
C.V.: Coefficient of Variation, the standard deviation expressed as a percentage of the mean. Calculated by dividing the Std Dev by the Mean and multiplying by 100 .

PRESS: Predicted Residual Error Sum of Squares - A measure of how the model fits each point in the design. The PRESS is computed by first predicting where each point should be from a model that contains all other points except the one in question. The squared residuals (difference between actual and predicted values) are then summed.

R-Squared: A measure of the amount of variation around the mean explained by the model.

1-(SSresidual / (SSmodel + SSresidual))

Adi R-Squared: A measure of the amount of variation around the mean explained by the model, adjusted for the number of terms in the model. The adjusted R-squared decreases as the number of terms in the model increases if those additional terms don't add value to the model.

1-((SSresidual / DFresidual) /((SSmodel + SSresidual) / (DFmodel + DFresidual) )

Pred R-Squared: A measure of the amount of variation in new data explained by the model.

1-(PRESS / (SStotal-SSblock)

The predicted $r$-squared and the adjusted $r$-squared should be within 0.20 of each other. Otherwise there may be a problem with either the data or the model.

Adequate Precision: This is a signal to noise ratio. It compares the range of the predicted values at the design points to the average prediction error. Ratios greater than 4 indicate adequate model discrimination.

## Post ANOVA and Prediction Equations

This section provides definitions for the post-ANOVA information for the individual terms.

Factor: Experimental variables selected for inclusion in the predictive model.
Coefficient Estimate: Regression coefficient representing the expected change in response y per unit change in x when all remaining factors are held constant. In orthogonal designs, it equals one half the factorial effect.

Coefficient Estimate for General Factorial Designs: Coefficients for multilevel categorical factors are not as simple to interpret. They do not have a physical meaning, but do have a mathematical meaning. $\beta 1$ is the difference of level 2 from the overall average. $\beta 2$ is the difference of level 3 from the overall average. $\beta \mathrm{k}$ is the difference of level $(\mathrm{k}+1)$ from the overall average. The negative sum of the coefficients will be the difference of level 1 from the overall average.

DF: Degrees of Freedom - equal to one for testing coefficients.
Standard Error: The standard deviation associated with the coefficient estimate.
$\mathbf{9 5 \%}$ CI High and Low: These two columns represent the range that the true coefficient should be found in $95 \%$ of the time. If this range spans 0 (one limit is positive
and the other negative) then the coefficient of 0 could be true, indicating the factor has no effect.

VIF: Variance Inflation Factor - Measures how much the variance of the model is inflated by the lack of orthogonality in the design. If the factor is orthogonal to all other factors in the model, the VIF is one. Values greater than 10 indicate that the factors are too correlated together (they are not independent.)

The predictive model: is listed in both actual and coded terms. The coded (or pseudo) equation is useful for identifying the relative significance of the factors by comparing the factor coefficients. This comparison cannot be made with the actual equation because the coefficients are scaled to accommodate the units of each factor. The equations give identical predictions. These equations, used for prediction, have no block effects. Blocking is a restriction on the randomization of the experiment, used to reduce error. It is not a factor being studied. Blocks are only used to fit the observed experiments, not to make predictions.

## Glossary of Terms

Factor: The independent variable to be manipulated in an experiment.
Level: The setting of a factor.
Response: A measurable product or process characteristic thought to be affected by the experimental factors.

Effect: The change in average response when a factor goes from its low level to its high level.

Modei: The model is the empirical mathematical model that is fit to the data.
Standard Order: A conventional "textbook" ordering of the array of low and high factor levels.

Actual Value: The measured response data for this particular run.
Predicted Value: The value predicted from the model, generated by using the prediction equation. Includes block and center point corrections, if present.


Appendix B
Data of Dependent Variables
Of Curcuminoids-PLGA Nanoparticles

จุฬาลงกรณ์มหาวิทยาลัย Chulalongkorn University

Table Appendix B-1. Nanoparticles recovery, curcuminoids content, and entrapment efficiency of formulation number 1 to 15

| Formulation number |  | Nanoparticles recovery <br> (\%) |  |  |  | Entrapment efficiency(\%) |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | 2-replicate | Average | 2-replicate | Average | 2-replicate | Average |
| 1 | Rep-1 | 61.49 | 69.03 | 0.0245 | 0.0244 | 0.75 | 0.80 |
|  | Rep-2 | 69.03 |  | 0.0243 |  | 0.84 |  |
| 2 | Rep-1 | 67.78 | 66.11 | 0.1106 | 0.0972 | 1.25 | 1.07 |
|  | Rep-2 | 64.44 |  | 0.0837 |  | 0.90 |  |
| 3 | Rep-1 | 68.73 | 64.82 | 0.0491 | 0.0625 | 0.56 | 0.67 |
|  | Rep-2 | 60.91 |  | 0.0759 |  | 0.77 |  |
| 4 | Rep-1 | 67.63 | $65.93$ | 0.1091 | 0.1101 | 0.74 | 0.73 |
|  | Rep-2 | 64.23 |  | 0.1110 |  | 0.71 |  |
| 5 | Rep-1 | 67.43 | 68.68 | 0.0538 | 0.0540 | 1.81 | 1.85 |
|  | Rep-2 | 69.93 |  | 0.0541 |  | 1.89 |  |
| 6 | Rep-1 | 57.64 | 62.50 | 0.0494 | 0.0454 | 1.42 | 1.41 |
|  | Rep-2 | 67.36 |  | 0.0414 |  | 1.39 |  |
| 7 | Rep-1 | 68.96 | 66.42 | 0.0905 | 0.0950 | 1.04 | 1.05 |
|  | Rep-2 | 63.88 |  | 0.0995 |  | 1.06 |  |
| 8 | Rep-1 | 63.19 | 61.31 | 0.0923 | 0.0952 | 0.97 | 0.97 |
|  | Rep-2 | 59.43 |  | 0.0981 |  | 0.97 |  |
| 9 | Rep-1 | 65.40 | 62.08 | 0.0872 | $0.0864$ | 0.95 | 0.89 |
|  | Rep-2 | 58.76 |  | 0.0855 |  | 0.84 |  |
| 10 | Rep-1 | 64.31 | 62.26 | 0.1167 | 0.1209 | 0.75 | 0.75 |
|  | Rep-2 | 60.21 |  | 0.1250 |  | 0.75 |  |
| 11 | Rep-1 | 66.72 | 63.54 | 0.0944 | 0.0932 | 0.63 | 0.59 |
|  | Rep-2 | 60.36 |  | 0.0920 |  | 0.56 |  |
| 12 | Rep-1 | 64.33 | 61.35 | 0.0444 | 0.0430 | 1.43 | 1.32 |
|  | Rep-2 | 58.37 |  | 0.0415 |  | 1.21 |  |
| 13 | Rep-1 | 66.34 | 67.54 | 0.0984 | 0.0984 | 1.09 | 1.11 |
|  | Rep-2 | 68.74 |  | 0.0984 |  | 1.13 |  |
| 14 | Rep-1 | 59.26 | 63.99 | 0.0621 | 0.0618 | 0.61 | 0.66 |
|  | Rep-2 | 68.72 |  | 0.0614 |  | 0.70 |  |
| 15 | Rep-1 | 68.70 | 68.02 | 0.1327 | 0.1389 | 0.91 | 0.94 |
|  | Rep-2 | 67.34 |  | 0.1450 |  | 0.98 |  |

Table Appendix B-2. Mean particle size and polydispersity index of formulation number 1 to 15

| Formulation <br> Number | Mean Particle Size <br> (nm) |  |  |  |  | Polydispersity Index |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | Rep-1 | Rep-2 | Rep-3 | Average | Rep-1 | Rep-2 | Rep-3 | Average |  |
| 1 | 310 | 300 | 310 | 307 | 0.57 | 0.60 | 0.60 | 0.59 |  |
| 2 | 320 | 320 | 320 | 320 | 0.85 | 0.82 | 0.82 | 0.83 |  |
| 3 | 320 | 320 | 320 | 320 | 0.76 | 0.79 | 0.76 | 0.77 |  |
| 4 | 320 | 320 | 320 | 320 | 0.75 | 0.73 | 0.74 | 0.74 |  |
| 5 | 330 | 330 | 330 | 330 | 0.85 | 0.83 | 0.84 | 0.84 |  |
| 6 | 310 | 300 | 310 | 313 | 0.76 | 0.74 | 0.75 | 0.75 |  |
| 7 | 320 | 320 | 320 | 320 | 0.81 | 0.79 | 0.83 | 0.81 |  |
| 8 | 320 | 320 | 320 | 320 | 0.70 | 0.73 | 0.70 | 0.71 |  |
| 9 | 300 | 310 | 290 | 300 | 0.70 | 0.68 | 0.69 | 0.69 |  |
| 10 | 320 | 320 | 320 | 320 | 0.72 | 0.73 | 0.71 | 0.72 |  |
| 11 | 310 | 310 | 310 | 310 | 0.72 | 0.73 | 0.74 | 0.73 |  |
| 12 | 300 | 310 | 310 | 307 | 0.75 | 0.75 | 0.78 | 0.76 |  |
| 13 | 310 | 320 | 330 | 320 | 0.78 | 0.75 | 0.78 | 0.77 |  |
| 14 | 310 | 310 | 310 | 310 | 0.80 | 0.83 | 0.80 | 0.81 |  |
| 15 | 310 | 300 | 300 | 303 | 0.82 | 0.84 | 0.86 | 0.84 |  |

Table Appendix B-3. Nanoparticles recovery, curcuminoids content, and entrapment efficiency of formulation number 16 to 30

| Formulation number |  | Nanoparticles recovery (\%) |  |  |  | Entrapment efficiency <br> (\%) |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | 2-replicate | Average | 2-replicate | Average | 2-replicate | Average |
| 16 | Rep-1 | 51.63 | 53.52 | 0.6457 | 0.6421 | 16.67 | 17.18 |
|  | Rep-2 | 55.41 |  | 0.6384 |  | 17.69 |  |
| 17 | Rep-1 | 54.37 | 52.67 | 2.2429 | 2.2860 | 20.32 | 20.06 |
|  | Rep-2 | 50.97 |  | 2.3291 |  | 19.79 |  |
| 18 | Rep-1 | 52.89 | 55.03 | 0.9764 | 0.9896 | 8.61 | 9.08 |
|  | Rep-2 | 57.17 |  | 1.0027 |  | 9.55 |  |
| 19 | Rep-1 | 56.97 | $54.10$ | 1.6791 | 1.6756 | 9.57 | 9.07 |
|  | Rep-2 | 51.23 |  | 1.6720 |  | 8.57 |  |
| 20 | Rep-1 | 50.20 | $46.43$ | 0.9035 | 0.9025 | 22.68 | 20.95 |
|  | Rep-2 | 42.66 |  | 0.9014 |  | 19.23 |  |
| 21 | Rep-1 | 59.76 | 56.14 | 0.5163 | 0.5236 | 15.43 | 14.68 |
|  | Rep-2 | 52.52 |  | 0.5309 |  | 13.94 |  |
| 22 | Rep-1 | 48.71 | 50.17 | 1.3669 | 1.3912 | 11.10 | 11.64 |
|  | Rep-2 | 51.63 |  | 1.4155 |  | 12.18 |  |
| 23 | Rep-1 | 52.89 | 57.23 | 1.4195 | 1.3908 | 12.51 | 13.25 |
|  | Rep-2 | 61.57 |  | 1.3621 |  | 13.98 |  |
| 24 | Rep-1 | 57.26 | 55.84 | 1.1138 | $1.1052$ | 10.63 | 10.29 |
|  | Rep-2 | 54.42 |  | 1.0966 |  | 9.95 |  |
| 25 | Rep-1 | 47.51 | 48.65 | 3.0050 | 2.9824 | 14.28 | 14.51 |
|  | Rep-2 | 49.79 |  | 2.9598 |  | 14.74 |  |
| 26 | Rep-1 | 55.26 | 51.33 | 1.3815 | 1.3881 | 7.63 | 7.12 |
|  | Rep-2 | 47.40 |  | i. 3946 |  | 6.61 |  |
| 27 | Rep-1 | 57.62 | 55.15 | 0.7255 | 0.7308 | 20.90 | 20.15 |
|  | Rep-2 | 52.68 |  | 0.7361 |  | 19.39 |  |
| 28 | Rep-1 | 55.94 | 56.38 | 1.9269 | 1.9241 | 17.97 | 18.08 |
|  | Rep-2 | 56.82 |  | 1.9212 |  | 18.19 |  |
| 29 | Rep-1 | 54.61 | 51.89 | 0.9453 | 0.9616 | 8.60 | 8.31 |
|  | Rep-2 | 49.17 |  | 0.9779 |  | 8.01 |  |
| 30 | Rep-1 | 53.48 | 52.44 | 1.8742 | 1.8614 | 10.02 | 9.76 |
|  | Rep-2 | 51.40 |  | 1.8486 |  | 9.50 |  |

Table Appendix B-4. Mean particle size and polydispersity index of formulation number 16 to 30

| Formulation <br> Number | Mean Particle Size <br> (nm) |  |  |  |  | Polydispersity Index |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | Rep-1 | Rep-2 | Rep-3 | Average | Rep-1 | Rep-2 | Rep-3 | Average |  |
| 16 | 290 | 300 | 300 | 297 | 1.01 | 1.05 | 1.06 | 1.04 |  |
| 17 | 330 | 340 | 330 | 333 | 1.19 | 1.20 | 1.21 | 1.20 |  |
| 18 | 280 | 280 | 280 | 280 | 0.82 | 0.80 | 0.78 | 0.80 |  |
| 19 | 320 | 310 | 320 | 317 | 1.14 | 1.08 | 1.17 | 1.13 |  |
| 20 | 320 | 320 | 320 | 320 | 1.30 | 1.34 | 1.35 | 1.33 |  |
| 21 | 290 | 270 | 280 | 280 | 0.72 | 0.69 | 0.72 | 0.71 |  |
| 22 | 330 | 330 | 330 | 330 | 0.87 | 0.89 | 0.85 | 0.87 |  |
| 23 | 320 | 320 | 320 | 320 | 0.98 | 0.99 | 0.94 | 0.97 |  |
| 24 | 330 | 320 | 310 | 320 | 1.03 | 0.98 | 1.02 | 1.01 |  |
| 25 | 320 | 330 | 320 | 323 | 1.01 | 0.97 | 1.11 | 1.03 |  |
| 26 | 310 | 320 | 320 | 317 | 0.88 | 0.89 | 0.90 | 0.89 |  |
| 27 | 300 | 310 | 310 | 307 | 1.12 | 1.14 | 1.13 | 1.13 |  |
| 28 | 320 | 310 | 310 | 313 | 1.55 | 1.54 | 1.56 | 1.55 |  |
| 29 | 270 | 280 | 260 | 270 | 1.08 | 1.10 | 1.06 | 1.08 |  |
| 30 | 340 | 330 | 330 | 333 | 0.86 | 0.92 | 0.89 | 0.89 |  |

Table Appendix B-5. Nanoparticles recovery, curcuminoids content, and entrapment efficiency of formulation number 31 to 45

| Formulation number |  | Nanoparticles recovery(\%) |  |  |  | Entrapment efficiency <br> (\%) |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | 2-replicate | Average | 2-replicate | Average | 2-replicate | Average |
| 31 | Rep-1 | 52.47 | 51.40 | 1.1165 | 1.1291 | 29.29 | 29.01 |
|  | Rep-2 | 50.33 |  | 1.1416 |  | 28.73 |  |
| 32 | Rep-1 | 50.79 | 53.63 | 2.8709 | 2.8942 | 24.30 | 25.88 |
|  | Rep-2 | 56.47 |  | 2.9175 |  | 27.46 |  |
| 33 | Rep-1 | 53.07 | 51.68 | 2.8005 | 2.9025 | 24.77 | 24.98 |
|  | Rep-2 | 50.29 |  | 3.0045 |  | 25.18 |  |
| 34 | Rep-1 | 46.92 | 49.92 | 4.5464 | 4.5606 | 21.33 | 22.77 |
|  | Rep-2 | 52.92 |  | 4.5748 |  | 24.21 |  |
| 35 | Rep-1 | 51.08 | 52.04 | 1.0610 | 1.0826 | 27.10 | 28.18 |
|  | Rep-2 | 53.00 |  | 1.1041 |  | 29.26 |  |
| 36 | Rep-1 | 49.37 | 47.54 | 1.0338 | 1.0545 | 25.52 | 25.05 |
|  | Rep-2 | 45.71 |  | 1.0752 |  | 24.57 |  |
| 37 | Rep-1 | 48.76 | 51.59 | 2.6492 | 2.6369 | 21.53 | 22.67 |
|  | Rep-2 | 54.42 |  | 2.6246 |  | 23.81 |  |
| 38 | Rep-1 | 56.84 | 54.51 | 2.3754 | 2.4048 | 22.50 | 21.84 |
|  | Rep-2 | 52.18 |  | 2.4342 |  | 21.17 |  |
| 39 | Rep-1 | 54.78 | 52.94 | 2.6657 | 2.7115 | 24.34 | 23.91 |
|  | Rep-2 | 51.10 |  | 2.7573 |  | 23.48 |  |
| 40 | Rep-1 | 49.67 | 54.33 | 3.9841 | 4.1865 | 19.79 | 22.84 |
|  | Rep-2 | 58.99 |  | 4.3889 |  | 25.89 |  |
| 41 | Rep-1 | 56.09 | 55.04 | 4.484? | 4.4771 | 25.15 | 24.64 |
|  | Rep-2 | 53.99 |  | 4.4699 |  | 24.13 |  |
| 42 | Rep-1 | 53.87 | 54.76 | 1.1921 | 1.1872 | 32.11 | 32.50 |
|  | Rep-2 | 55.65 |  | 1.1823 |  | 32.90 |  |
| 43 | Rep-1 | 52.89 | 53.24 | 2.7615 | 2.9669 | 24.34 | 26.34 |
|  | Rep-2 | 53.59 |  | 3.1723 |  | 28.33 |  |
| 44 | Rep-1 | 54.05 | 52.38 | 3.3429 | 3.3239 | 30.11 | 29.02 |
|  | Rep-2 | 50.71 |  | 3.3049 |  | 27.93 |  |
| 45 | Rep-1 | 51.64 | 53.51 | 4.8107 | 5.0000 | 24.84 | 26.79 |
|  | Rep-2 | 55.38 |  | 5.1892 |  | 28.74 |  |

Table Appendix B-6. Mean particle size and polydispersity index of formulation number 31 to 45

| Formulation <br> Number | Mean Particle Size <br> (\%) |  |  |  | Polydispersity Index |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | Rep-1 | Rep-2 | Rep-3 | Average | Rep-1 | Rep-2 | Rep-3 | Average |
| 31 | 370 | 360 | 360 | 363 | 0.92 | 0.94 | 0.90 | 0.92 |
| 32 | 320 | 330 | 330 | 327 | 0.85 | $n .87$ | 0.89 | 0.87 |
| 33 | 390 | 380 | 380 | 383 | 0.94 | 0.96 | 0.95 | 0.95 |
| 34 | 360 | 350 | 350 | 353 | 0.86 | 0.87 | 0.91 | 0.88 |
| 35 | 360 | 370 | 360 | 363 | 0.92 | 0.92 | 0.92 | 0.92 |
| 36 | 390 | 400 | 400 | 397 | 0.85 | 0.86 | 0.84 | 0.85 |
| 37 | 390 | 380 | 400 | 390 | 0.97 | 0.94 | 0.97 | 0.96 |
| 38 | 390 | 380 | 390 | 387 | 0.92 | 0.94 | 0.93 | 0.93 |
| 39 | 380 | 390 | 380 | 383 | 0.99 | 0.97 | 1.01 | 0.99 |
| 40 | 380 | 380 | 380 | 380 | 0.94 | 0.98 | 0.99 | 0.97 |
| 41 | 410 | 390 | 400 | 400 | 0.86 | 0.89 | 0.86 | 0.87 |
| 42 | 400 | 400 | 400 | 400 | 0.99 | 0.94 | 0.98 | 0.97 |
| 43 | 390 | 390 | 400 | 393 | 0.94 | 0.92 | 0.93 | 0.93 |
| 44 | 420 | 430 | 420 | 423 | 0.94 | 0.95 | 0.93 | 0.94 |
| 45 | 390 | 400 | 400 | 397 | 0.97 | 0.93 | 0.98 | 0.96 |



Appendix C

# Standard Curve and HPLC Chromatogram of Curcuminoids 



Table Appendix C-1. Peak area from HPLC analysis of curcuminoids at concentration 0.02 to $0.10 \mathrm{mg} / \mathrm{ml}$

| Concentration <br> (mg/ml) | Peak area (x 1,000) |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | $\mathbf{1}$ | $\mathbf{2}$ | $\mathbf{3}$ | Mean | $\pm$ | S.D. |  |
| 0.02 | 3,649 | 3,673 | 3,656 | 3,659 | $\pm$ | 1.28 |  |
| 0.04 | 7,660 | 7,638 | 7,633 | 7,644 | $\pm$ | 14.08 |  |
| 0.06 | 11,245 | 11,257 | 11,210 | 11,237 | $\pm$ | 24.13 |  |
| 0.08 | 14,999 | 15,137 | 14,896 | 15,011 | $\pm$ | 120.71 |  |
| 0.10 | 18,393 | 18,551 | 18,426 | 18,457 | $\pm$ | 83.39 |  |

Standard Curve
Peak area


Figure Appendix C-1. Calibration curve of curcuminoids


Figure Appendix C-2. HPLC-Chromatogram of curcuminoids
a) Curcumin (retention time 11.966)
b) Desmethoxycurcumin (retention time 10.880)
c) Bisdesmethoxycurcumin (retention time 9.889)


## Appendix D

Design-Expert ${ }^{\circledR}$ output of statistical analysis


จุฬาลงกรณ์มหาวิทยาลัย

Table Appendix D-1. Design-Expert® output for fitting a regression model to the nanoparticles recovery of formulation number 1 to 15


Table Appendix D-2. Design-Expert® output of ANOVA for the reduced model of correlation between formulation ingredients and the nanoparticles recovery of formulation number 1 to 15

| Response: Nanoparticles recovery |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Backward Elimination Regression with Alpha to Exit $=0.050$ |  |  |  |  |  |
| Forced Terms Intercept |  |  |  |  |  |
| Removed | Coefficient | t for H 0 |  |  |  |
|  | Estimate | Coeff $=0$ | Prob $>\|\boldsymbol{t}\|$ | R-Squared | MSE |
| A | -0.15 | -0.16 | 0.8788 | 0.5671 | 6.05 |
| $\mathrm{B}^{2}$ | 0.25 | 0.20 | 0.8516 | 0.5643 | 5.22 |
|  | 0.24 | 0.30 | 0.7705 | 0.5586 | 4.63 |
| A ${ }^{\text {B }}$ | -0.56 | -0.53 | 0.6137 | 0.5434 | 4.26 |
| $\mathrm{C}^{2}$ | 0.71 | 0.66 | 0.5262 | 0.5214 | 4.02 |
| $\mathrm{A}^{2}$ | 1.55 | 1.49 | 0.1658 | 0.4144 | 4.47 |
| AC | 1.50 | 1.42 | 0.1835 | 0.3071 | 4.84 |
|  | -1.22 | -1.56 | 0.1437 | 0.1658 | 5.38 |
| BC | 1.87 | 1.61 | 0.1319 | -0.0000 | 5.99 |
| ANOVA for | Response Surface | ean Mod | $s]$ |  |  |
| Source | Sum of | Recers Mean |  | FValue | Prob $>$ F |
|  | Squares | DF | Square |  |  |
| Model | 0000 |  |  | Value |  |
| Residual | 83.91 | 14 | 5.99 |  |  |
| Lack of Fit | 68.73 | 12 | 5.73 | 0.75 | 0.6980 |
| Pure Error | 15.18 - 2 |  | 7.59 |  |  |
| Cor Total | 83.91 | 14 |  |  |  |
| Std. Dev. | 2.45 | , |  | R-Squared | 0.0000 |
| Mean | 64.65 |  |  | R-Squared | 0.0000 |
| C.V. | 3.79 |  |  | R-Squared | - 0.1480 |
| PRESS | 96.32 |  | Adeq Precision |  |  |
|  | Coefficient |  | tandard | 95\% CI | 95\% CI |
| Factor | Estimate | DF | Error | Low | High |
| Intercept | 64.65 | 1 | 0.63 | 63.30 | 66.01 |

Final Equation in Terms of Coded Factors:

$$
\text { Recovery }=+64.65
$$

Final Equation in Terms of Actua! Factors:

```
Recovery = +64.65400
```

Table AppendixD-3. Design-Expert®® output for fitting a regression model to the particle size of̂ formulation number 1 to 15

| Response: | Particle Size |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
| *** WARNING: The Cubic Model is Aliased! *** |  |  |  |  |  |
| Sequential Model Sum of Squares |  |  |  |  |  |
|  | Sum of |  | Mean | F |  |
| Source | Squares | DF | Square | Value | Prob $>$ F |
| Mean | $1.486 \mathrm{E}+006$ | 1 | $1.486 \mathrm{E}+006$ |  |  |
| Linear | 266.14 | 3 | 88.71 | 1.46 | 0.2797 |
| 2 FI | 97.51 | 3 | 32.50 | 0.45 | 0.7215 |
| Quadratic | 201.35 | 3 | J 67.12 | 0.90 | 0.5011 |
| Cubic | 104.36 | 3 | 34.79 | 0.26 | 0.8508 |
| Residual | 266.67 | 2 | 133.33 |  |  |
| Total | $1.487 \mathrm{E}+006$ | 15 | 99119.47 |  |  |
| Lack of Fit Tests |  |  |  |  |  |
|  | Sum of |  | Mean | F |  |
| Source | Squares |  | Square | Value | Prob $>$ F |
| Linear | 403.22 | 9 | 44.80 | 0.34 | 0.8982 |
| 2FI | 305.71 | 6 | 50.95 | 0.38 | 0.8476 |
| Quadratic | 104.36 |  | 34.79 | 0.26 | 0.8508 |
| Cubic | 0.000 | 0 | Se-pereves |  |  |
| Pure Error | 266.67 | 2 | 133.33 |  |  |
| Model Summary Statistics |  |  |  |  |  |
|  | Std. |  | Adjusted | Predicted |  |
| Source | Dev. | R-Squared | R-Squared | R-Squared | PRESS |
| Linear | 7.80 | 0.2843 | 0.0892 | -0.2433 | 1163.80 |
| 2FI | 8.46 | 0.3885 | -0.0701 | -1.0401 | 1909.59 |
| Quadratic | 8.61 | HU0.6036 | - 0.1099 | -1.4249 | 2269.80 |
| Cubic | 11.55 | 0.7151 | -0.9942 |  | + |
| + Case(s) with leverage of 1.0000: PRESS statistic not defined |  |  |  |  |  |

Table AppendixD-4. Design-Expert® output of ANOVA for the reduced model of correlation between formulation ingredients and the particle size of formulation number 1 to 15

## Response: Particle Size

Backward Elimination Regression with Alpha to Exit $=\mathbf{0 . 0 5 0}$

| Forced Terms | Intercept |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Coefficient | $\mathbf{t}$ for H0 |  |  |  |  |
| Removed | Estimate | Coeff $=\mathbf{0}$ | Prob > \|t| | R-Squared | MSE |
| B | -0.54 | -0.18 | 0.8656 | 0.6011 | 62.23 |
| B $^{2}$ | -1.54 | -0.38 | 0.7202 | 0.5917 | 54.59 |
| BC | 1.67 | 0.45 | 0.6654 | 0.5798 | 49.16 |
| A $^{2}$ | -2.26 | -0.62 | 0.5525 | 0.5597 | 45.80 |
| AC | -2.50 | -0.74 | 0.4788 | 0.5329 | 43.72 |
| AB | -3.92 | -1.18 | 0.2634 | 0.4674 | 45.32 |
| A | -3.46 | -1.45 | 0.1741 | 0.3651 | 49.52 |
| C | -4.58 | -1.84 | 0.0903 | 0.1855 | 58.64 |
| C $^{2}$ | 6.82 | 1.72 | 0.1090 | 0.0000 | 66.86 |

ANOVA for Response Surface Mean Model


## Final Equation in Terms of Coded Factors:

$$
\text { Particle Size }=+314.73
$$

Final Equation in Terms of Actual Factors:

$$
\text { Particle Size }=+314.73333
$$

Table AppendixD-5. Design-Expert® output for fitting a regression model to the polydispersity index of formulation number 1 to 15


Table AppendixD-6. Design-Expert® output of ANOVA for the reduced model of correlation between formulation ingredients and the polydispersity index of formulation number 1 to 15

Response: Polydispersity
Backward Elimination Regression with Alpha to Exit $=0.050$
Forced Terms Intercept

| Removed | Coefficient <br> Estimate | $\mathbf{t}$ for $\mathbf{H} \mathbf{0}$ <br> Coeff $=\mathbf{0}$ | Prob $>\|\boldsymbol{t}\|$ | R-Squared | MSE |
| :---: | :---: | :---: | :---: | :---: | :---: |
| $\mathrm{A}^{2}$ | 0.015 | 0.35 | 0.7424 | 0.4006 | $6.203 \mathrm{E}-003$ |
| B | 0.011 | 0.40 | 0.7002 | 0.3843 | $5.462 \mathrm{E}-003$ |
| AB | -0.017 | -0.47 | 0.6502 | 0.3646 | $4.932 \mathrm{E}-003$ |
| C | -0.012 | -0.50 | 0.6282 | 0.3444 | $4.523 \mathrm{E}-003$ |
| $\mathrm{~B}^{2}$ | -0.021 | -0.60 | 0.5664 | 0.3186 | $4.231 \mathrm{E}-003$ |
| BC | 0.025 | 0.77 | 0.4598 | 0.2784 | $4.074 \mathrm{E}-003$ |
| AC | 0.025 | 0.78 | 0.4499 | 0.2381 | $3.942 \mathrm{E}-003$ |
| $\mathrm{C}^{2}$ | 0.043 | 1.33 | 0.2083 | 0.1258 | $4.175 \mathrm{E}-003$ |
| A | 0.031 | 1.37 | 0.1945 | 0.0000 | $4.435 \mathrm{E}-003$ |

ANOVA for Response Surface Mean Model
Analysis of variance table [Partial sum of squares]


Final Equation in Terms of Coded Factors:
Polydispersity index $=+0.76$
Final Equation in Terms of Actual Factors:
Polydispersity index $=+0.75733$

Table AppendixD-7. Design-Expert® output for fitting a regression model to the curcuminoids content of formulation number 1 to 15

| Response: Curcuminoids content |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
| *** WARNING: The Cubic Model is Aliased! *** |  |  |  |  |  |
| Sequential Model Sum of Squares |  |  |  |  |  |
|  | Sum of |  | Mean | F |  |
| Source | Squares | s DF | Square | Value | Prob $>$ F |
| Mean | 0.10 | 01 | 0.10 |  |  |
| Linear | 0.013 | 3 | $4.233 \mathrm{E}-003$ | 29.70 | $<0.0001$ |
| 2FI | $1.178 \mathrm{E}-004$ | 3 | $3.927 \mathrm{E}-005$ | 0.22 | 0.8822 |
| Quadratic | $4.151 \mathrm{E}-004$ | 3 | $1.384 \mathrm{E}-004$ | 0.67 | 0.6069 |
| Cubic | $9.847 \mathrm{E}-004$ | 3 | $3.282 \mathrm{E}-004$ | 13.00 | 0.0722 |
| Residual | $5.048 \mathrm{E}-005$ | - 2 | $2.524 \mathrm{E}-005$ |  |  |
| Total | $0.11$ | 15 | 7.633E-003 |  |  |
| Lack of Fit Tests |  |  |  |  |  |
|  | Sum of |  | Mean | F |  |
| Source | Squares | S | Square | Value | Prob $>$ F |
| Linear | $1.518 \mathrm{E}-003$ |  | $1.686 \mathrm{E}-004$ | 6.68 | 0.1369 |
| 2FI | $1.400 \mathrm{E}-003$ | - | $2.333 \mathrm{E}-004$ | 9.24 | 0.1008 |
| Quadratic | $9.847 \mathrm{E}-004$ |  | 3.282E-004 | 13.00 | 0.0722 |
| Cubic | 0.000 | 0 |  |  |  |
| Pure Error | $5.048 \mathrm{E}-005$ | - 2 | 2.524E-005 |  |  |
| Model Summary Statistics |  |  |  |  |  |
|  | Std. |  | Adjusted | Predicted |  |
| Source | Dev. R | R-Squared | R-Squared | R-Squared | PRESS |
| Linear | 0.012 | 0.8901 | 0.8601 | 0.7910 | 2.982E-003 |
| 2FI | 0.013 | 0.8984 | 0.8221 | 0.5696 | $6.141 \mathrm{E}-003$ |
| Quadratic | 0.014 | 0.9274 | $\bigcirc 0.7969$ | - -0.1122 | 0.016 |
| Cubic 5.02 | E-003 | 0.9965 | 0.0 .9752 |  | + |
| + Case(s) with leverage of 1.0000: PRESS statistic not defined |  |  |  |  |  |

Table Appendix D-8. Design-Expert® output of ANOVA for the reduced model of correlation between formulation ingredients and the curcuminoids content of formulation number 1 to 15

| Response: | Curcuminoids content |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Backward Elimination Regression with Alpha to Exit $=0.050$ |  |  |  |  |  |
| Forced Terms | Intercept |  |  |  |  |
| Removed | Coefficient Estimate | t for H 0 <br> Coeff=0 | Prob $>\|t\|$ | R-Squared | MSE |
| A | 5.975E-003 | 1.42 | 0.1846 | 0.8701 | $1.545 \mathrm{E}-004$ |

ANOVA for Response Surface Reduced Linear Model
Analysis of variance table [Partial suin of squares]

| Source | Sum of <br> Squares | DF | Mean <br> Square | Falue | Prob > F |
| :--- | ---: | ---: | ---: | ---: | ---: |
| Model | 0.012 | 2 | $6.207 \mathrm{E}-003$ | 40.18 | $<0.0001$ |
| B | 0.011 | 1 | 0.011 | 70.99 | $<0.0001$ |
| C | $1.447 \mathrm{E}-003$ | 1 | $1.447 \mathrm{E}-003$ | 9.37 | 0.0099 |
| Residual | $1.854 \mathrm{E}-003$ | 12 | $1.545 \mathrm{E}-004$ |  |  |
| Lack of Fit | $1.803 \mathrm{E}-003$ | 10 | $1.803 \mathrm{E}-004$ | 7.14 | 0.1289 |
| Pure Error | $5.048 \mathrm{E}-005$ | 2 | $2.524 \mathrm{E}-005$ |  |  |
| Cor Total | 0.014 | 14 |  |  |  |


|  |  |  |  |
| :--- | ---: | ---: | ---: |
| Std. Dev. | 0.012 | R-Squared | 0.8701 |
| Mean | 0.082 | Adj R-Squared | 0.8484 |
| C.V. | 15.21 | Pred R-Squared | 0.7902 |
| PRESS | $2.993 E-003$ | Adeq Precision | 18.162 |


|  | Coefficient LALONGIOROStandard | SRO CI | 95\% CI |  |  |  |
| :--- | ---: | ---: | ---: | ---: | ---: | ---: |
| Factor | Estimate | DF | Error | Low | High | VIF |
| Intercept | 0.082 | 1 | $3.209 \mathrm{E}-003$ | 0.075 | 0.089 |  |
| B-Curcuminoids | 0.037 | 1 | $4.394 \mathrm{E}-003$ | 0.027 | 0.047 | 1.00 |
| C-Vit E TPGS | -0.013 | 1 | $4.394 \mathrm{E}-003$ | -0.023 | $-3.876 \mathrm{E}-003$ | 1.00 |

Final Equation in Terms of Coded Factors:

$$
\text { Content }=+0.082+0.037 * \mathrm{~B}-0.013 * \mathrm{C}
$$

Final Equation in Terms of Actual Factors:

$$
\text { Content }=+0.059828+9.25625 \mathrm{E}-003 * \text { Curcuminoids }-6.72500 \mathrm{E}-003 * \text { Vit E TPGS }
$$

Table Appendix D-9. Design-Expert® output for fitting a regression model to the entrapment efficiency of formulation number 1 to 15

| Response: | Entrapment Efficiency |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Transform: | Inverse |  |  |  |  |
| *** WARNING: The Cubic Model is Aliased! *** |  |  |  |  |  |
| Sequential Model Sum of Squares |  |  |  |  |  |
|  | Sum of |  | Mean | F |  |
| Source | Squares | DF | Square | Value | Prob $>$ F |
| Mean | 14.61 | 1 | 14.61 |  |  |
| Linear | 1.02 | 3 | 0.34 | 6.44 | 0.0089 |
| 2FI | 0.042 | 3 | 0.014 | 0.21 | 0.8871 |
| Quadratic | 0.17 | 3 | 0.058 | 0.80 | 0.5457 |
| Cubic | 0.35 | 3 | 0.12 | 18.84 | 0.0508 |
| Residual | 0.012 | 2 | 6.217E-003 |  |  |
| Total | 16.21 | 15 | 1.08 |  |  |
| Lack of Fit Tests |  |  |  |  |  |
|  | Sum of |  | Mean | F |  |
| Source | Squares | DF | Square | Value | Prob $>$ F |
| Linear | 0.57 | 9 | 0.063 | 10.15 | 0.0929 |
| 2FI | 0.53 | 6 | $=0.088$ | 14.09 | 0.0677 |
| Quadratic | 0.35 | 3 | 0.12 | 18.84 | 0.0508 |
| Cubic | 0.000 | 0 |  |  |  |
| Pure Error | 0.012 | 2 | ك.217E-003 |  |  |
| Model Summary Statistics |  |  |  |  |  |
|  | Std. |  | Adjusted | Predicted |  |
| Source | Dev. | R-Squared | R-Squared | R-Squared | PRESS |
| Linear | 0.23 | 0.6372 | 0.5383 | 0.2312 | 1.23 |
| 2FI | 0.26 | 0.6637 | 0.4114 | -0.7571 | 2.81 |
| Quadratic | 0.27 | 0.7726 | 0.3632 | -2.5320 | 5.65 |
| Cubic | 0.079 | 0.9922 | 0.9456 |  | + |
| + Case(s) with leverage of 1.0000: PRESS statistic not defined |  |  |  |  |  |

Table Appendix D-10. Design-Expert® output of ANOVA for the reduced model of correlation between formulation ingredients and the entrapment efficiency of formulation number 1 to 15


ANOVA for Response Surface Reduced Linear Model
Analysis of variance table [Partial sum of squares]

|  | Sum of <br> Squares | DF | Mean <br> Square | F <br> Value | Prob > F |
| :--- | ---: | ---: | ---: | ---: | ---: |

## Final Equation in Terms of Coded Factors:

$$
\text { Entrapment Efficiency }=+0.99-0.30 * B
$$

Final Equation in Terms of Actual Factors:

$$
\text { Entrapment Efficiency }=+1.43182-0.074172 * \text { Curcuminoids }
$$

Table Appendix D-11. Design-Expert® output for fitting a regression model to the nanoparticles recovery of formulation number 16 to 30


Table Appendix D-12. Design-Expert® output of ANOVA for the reduced model of correlation between formulation ingredients and the nanoparticles recovery of formulation number 16 to 30


Final Equation in Terms of Coded Factors:

$$
\text { Recovery }=+53.13
$$

Final Equation in Terms of Actual Factors:

```
Recovery = +53.13133
```

Table Appendix D-13. Design-Expert® output for fitting a regression model to the particle size of formulation number 16 to 30


Table Appendix D-14. Design-Expert® output of ANOVA for the reduced model of correlation between formulation ingredients and the particle size of formulation number 16 to 30

| Response: Particle size |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Backward Elimination Regression with Alpha io Exit $=0.050$ |  |  |  |  |  |
| Forced Terms | Intercept |  |  |  |  |
|  | Coefficient Estimate | t for H0 Coeff=0 | Prob $>$ \|t| | R-Squared | MSE |
| A | -0.50 | -0.10 | 0.9214 | 0.6146 | 180.03 |


| ANOVA for Response Surface Reduced Linear Model |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Source | Sum of Squares |  | $\begin{aligned} & \text { Mean } \\ & \text { Square } \end{aligned}$ | Value |  |
|  |  | DF |  |  | Prob $>$ F |
| Model | 3445.00 | 2 | 1722.50 | 9.57 | 0.0033 |
| B | 924.50 | 1 | 924.50 | 5.14 | 0.0427 |
| C | 2520.50 | 1 | 2520.50 | 14.00 | 0.0028 |
| Residual | 2160.33 | 12 | 180.03 |  |  |
| Lack of Fit | 2093.67 | 10 | 209.37 | 5.28 | 0.1451 |
| Pure Error | 66.67 | 2 | 33.33 |  |  |
| Cor Total | 5605.33 | 14 |  |  |  |


| Std. Dev. | 13.42 | R-Squared | 0.6146 |
| :--- | ---: | ---: | ---: |
| Mean | 310.67 | Adj R-Squared | 0.5504 |
| C.V. | 4.32 | Pred R-Squared | 0.3986 |
| PRESS | 3371.24 | Adeq Precision | 9.499 |


|  | Coefficient |  | Standard | 95\% CI | 95\% CI |  |
| :--- | ---: | ---: | ---: | ---: | ---: | ---: |
| Factor | Estimate | DF | Error | Low | High | VIF |
| Intercept | 310.67 | 1 | 3.46 | 303.12 | 318.21 |  |
| B-Curcuminoids | 10.75 | 1 | 4.74 | 0.41 | 21.09 | 1.00 |
| C-Polo天amer 407 | -17.75 | 1 | 4.74 | -28.09 | -7.41 | 1.00 |

## Final Equation in Terms of Coded Factors:

$$
\text { Particle size }=+310.67+10.75 * \mathrm{~B}-17.75 * \mathrm{C}
$$

Final Equation in Terms of Actual Factors:

```
Particle size = +365.54167+2.68750 * Curcuminoids - 5.91667 * Poloxamer 407
```

Table Appendix D-15. Design-Expert® output for fitting a regression model to the polydispersity index of formulation number 16 to 30

| Response: Polydispersity Index |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
| *** WARNING: The Cubic Model is Aliased! *** |  |  |  |  |  |
| Sequential Model Sum of Squares |  |  |  |  |  |
|  | Sum of |  | Mean | F |  |
| Source | Squares | DF | Square | Value | Prob $>$ F |
| Mean | 16.29 | 1 | 16.29 |  |  |
| Linear | 0.37 | $\underline{3}$ | 0.12 | 5.14 | $\underline{0.0183}$ |
| 2FI | 0.086 | 3 | 0.029 | 1.29 | 0.3422 |
| Quadratic | 0.090 | 3 | 0.030 | 1.70 | 0.2820 |
| Cubic | 0.078 | 3 | ] 0.026 | 4.98 | 0.1718 |
| Residual | 0.010 | 2 | 5.200E-003 |  |  |
| Total | 16.92 | 15 | 1.13 |  |  |
| Lack of Fit Tests |  |  |  |  |  |
|  | Sum of |  | Mean | F |  |
| Source | Squares | DF | Square | Value | Prob $>$ F |
| Linear | 0.25 |  | 0.028 | 5.41 | 0.1656 |
| 2FI | 0.17 |  | 0.028 | 5.36 | 0.1654 |
| Quadratic | 0.078 |  | 0.026 | 4.98 | 0.1718 |
| Cubic | 0.000 |  |  |  |  |
| Pure Error | 0.010 | 2 | $5.200 \mathrm{E}-003$ |  |  |
| Model Summary Statistics |  |  |  |  |  |
|  | Std. |  | Adjusted | Predicted |  |
| Source | Dev. | R-Squared | R-Scuared | R-Squared | PRESS |
| Linear | 0.15 | 0.5838 | $\bigcirc 0.4703$ | 0.1647 | $\underline{0.53}$ |
| 2FI | 0.15 | 0.7195 | 0.2 .5092 | -0.2577 | 0.80 |
| Quadratic | 0.13 | 0.8610 | 0.6109 | -0.9977 | 1.27 |
| Cubic | 0.072 | HU0.9836 | Uh 0.8851 | STT | + |
| + Case(s) with leverage of 1.0000: PRESS statistic not defined |  |  |  |  |  |

Table AppendixD-16. Design-Expert® output of ANOVA for the reduced model of correlation between formulation ingredients and the polydispersity index of formulation number 16 to 30

Response: Polydispersity Index
Backward Elimination Regression with Alpha to Exit $=0.050$
Forced Terms Intercept

| Removed | Coefficient <br> Estimate | $\mathbf{t}$ for H0 <br> Coeff $=\mathbf{0}$ | Prob $>\|\mathbf{t}\|$ | R-Squared | MSE |
| :---: | :---: | :---: | :---: | :---: | :---: |
| B | -0.034 | -0.62 | 0.5502 | 0.5694 | 0.023 |
| A | 0.060 | 1.13 | 0.2825 | 0.5240 | 0.023 |

ANOVA for Response Surface Reduced Linear Model
Analysis of variance table [Partial sum of squares]

|  | Sum of <br> Squares | DF | Mean | Fquare | Value |
| :--- | ---: | ---: | ---: | ---: | ---: |$\quad$ Prob > F


|  | Coefficient LALONGKOR Standard | 95\% CI | 95\% CI |  |  |  |
| :--- | ---: | ---: | ---: | ---: | ---: | ---: |
| Factor | Estimate | DF | Error | Low | High | VIF |
| Intercept | 1.04 | 1 | 0.039 | 0.96 | 1.13 |  |
| C-Poloxamer 407 | -0.20 | 1 | 0.054 | -0.32 | -0.087 | 1.00 |

Final Equation in Terms of Coded Factors:
Polydispersity index $=+1.04-0.20 * \mathrm{C}$

Final Equation in Terms of Actual Factors:

```
Polydispersity index = +1.85700-0.067917* Poloxamer 407
```

Table Appendix D-17. Design-Expert ${ }^{\circledR}$ output for fitting a regression model to the curcuminoids content of formulation number 16

| Response: Curcuminoids Content |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Sequential Model Sum of Squarcs |  |  |  |  |  |
|  | Sum of |  | Mean | F |  |
| Source | Squares | DF | Square | Value | Prob $>$ F |
| Mean | 28.72 | 1 | 28.72 |  |  |
| Linear | 5.50 | 3 | 1.83 | 24.26 | $<0.0001$ |
| 2FI | 0.40 | 3 | 0.13 | 2.47 | 0.1367 |
| Quadratic | 0.24 | 3 | 0.079 | 2.01 | 0.2315 |
| Cubic | 0.14 | 3 | 0.047 | 1.73 | 0.3864 |
| Residual | 0.054 | 2 | 0.027 |  |  |
| Total | 35.05 | 15 | 2.34 |  |  |
| Lack of Fit Tests |  |  |  |  |  |
|  | Sum of |  | Mean | F |  |
| Source | Squares | DF | Square | Value | Prob > F |
| Linear | 0.78 |  | 0.086 | 3.17 | 0.2627 |
| 2FI | 0.38 | 6 | 0.063 | 2.31 | 0.3325 |
| Quadratic | 0.14 | 3 | 0.047 | 1.73 | 0.3864 |
| Cubic | 0.000 |  |  |  |  |
| Pure Error | 0.054 |  | 0.027 |  |  |
| Model Summary Statistics |  |  |  |  |  |
|  | Std. |  | Adjusted | Predicted |  |
| Source | Dev. | R-Squared | R-Squared | R-Squared | PRESS |
| Linear | 0.27 | 0.8687 | 0.8329 | 0.7310 | 1.70 |
| 2FI | 0.23 | 0.9318 | 0.8806 | 0.6880 | 1.98 |
| Quadratic | 0.20 | 0.9691 | 0.9134 | 0.6232 | 2.39 |
| Cubic | 0.17 | 0.9914 | 0.9398 |  | + |
| + Case(s) with leverage of 1.0000: PRESS statistic not defined |  |  |  |  |  |

Table Appendix D-18. Design-Expert ${ }^{\circledR}$ output of ANOVA for the reduced model of correlation between formulation ingredients and the curcuminoids content of formulation number 16 to 30

Response: Curcuminoids content
Backward Elimination Regression with Alpha to Exit $=0.050$
Forced Terms Intercept

| Removed | Coefficient <br> Estimate | $\mathbf{t}$ for $\mathrm{H} \mathbf{0}$ <br> Coeff $=\mathbf{0}$ | Prob $>\|\mathbf{t}\|$ | R-Squared | MSE |
| :---: | :---: | :---: | :---: | :---: | :---: |
| A | -0.014 | -0.15 | 0.8848 | 0.8684 | 0.069 |

ANOVA for Response Surface Reduced Quadratic Model Analysis of variance table [Partial sum of squares]
Analysis of variance table [Partial sum of squares]

Sum of $\quad$\begin{tabular}{r}
Mean <br>
Source <br>
Squares

$\quad$

DF <br>
Model
\end{tabular}

|  |  |  |  |
| :--- | ---: | :--- | ---: |
| Std. Dev. | 0.26 |  | R-Squared |
| Mean | 1.38 | Adj R-Squared | 0.8685 |
| C.V. | 19.04 | Pred R-Squared | 0.7619 |
| PRESS | 1.51 |  | Adeq Precision |
|  |  | 19.815 |  |


|  | Coefficient <br> Estimate | DF | Standard <br> Error | 95\% CI <br> Low | 95\% CI <br> High | VIF |
| :--- | :---: | :---: | :---: | :---: | :---: | :---: |
| Factor |  | 1 | - |  |  |  |
| Intercept | 1.38 | 1 | 0.068 | 1.24 | 1.53 |  |
| B-Curcuminoids | 0.64 | 1 | 0.093 | 0.44 | 0.84 | 1.00 |
| C-Polxamer 407 | -0.53 | 1 | 0.093 | -0.73 | -0.33 | 1.00 |

Final Equation in Terms of Coded Factors:
Curcuminoids content $=+1.38+0.64 * B-0.53 * \mathrm{C}$

Final Equation in Terms of Actual Factors:

```
Curcuminoids content = +2.54184+0.15964*Curcuminoids - 0.17634* Poloxamer407
```

Table Appendix D-19. Design-Expert ${ }^{\circledR}$ output for fitting a regression model to the entrapment efficiency of formulation number 16 to 30


Table Appendix D-20. Design-Expert® output of ANOVA for the reduced model of correlation between formulation ingredients and the entrapment efficiency of formulation number 16 to 30

| Response: Entrapment Efficiency |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Backward Elimination Regression with Alpha to Exit $=0.050$ |  |  |  |  |  |  |
| Forced Terms Intercept |  |  |  |  |  |  |
| Removed | Coefficient <br> d Estimate | t for $\mathrm{H}_{0}$ <br> Coeff=0 | Prob $>$ \|t| | R-Squared | MSE |  |
| A | 0.11 | 0.18 | 0.8568 | 0.8912 | 2.85 |  |
| ANOVA for Response Surface Reduced Linear Model |  |  |  |  |  |  |
|  | Sum of |  | Mean | F |  |  |
| Source | Squares | DF | Square | Value | Prob $>$ F |  |
| Model | 280.11 | 2 | 140.05 | 49.14 | $<0.0001$ |  |
| B | 132.28 | 1 | 132.28 | 46.41 | < 0.0001 |  |
| C | 147.83 | 1 | 147.83 | 51.87 | $<0.0001$ |  |
| Residual | 34.20 | 12 | - 2.85 |  |  |  |
| Lack of Fit | 29.75 | 10 | -4. 2.97 | 1.34 | 0.5023 |  |
| Pure Error | 4.46 | 2 | - 2.23 |  |  |  |
| Cor Totai | 314.31 |  |  |  |  |  |
| Std. Dev. | 1.69 |  |  | R -Squared | 0.8912 |  |
| Mean | 13.61 |  | A | R-Squared | 0.8730 |  |
| C.V. | 12.40 | - | Pr | R-Squared | 0.8387 |  |
| PRESS | $50.71$ |  | กวิง | Precision | 22.159 |  |
|  | Coefficient |  | Standard | 95\% CI | 95\% CI |  |
| Factor | Estimate | DF | Error | Low | High | VIF |
| Intercept | 13.61 | 1 | 0.44 | 12.66 | 14.56 |  |
| B-Curcuminoids | -4.07 | 1 | 0.60 | -5.37 | -2.77 | 1.00 |
| C-Polxamer 407 | -4.30 | 1 | 0.60 | -5.60 | -3.00 | 1.00 |

## Final Equation in Terms of Coded Factors:

$$
\text { Entrapment Efficiency }=+13.61-4.07 * \mathrm{~B}-4.30 * \mathrm{C}
$$

## Final Equation in Terms of Actual Factors:

$$
\text { Entrapment Efficiency }=+36.90571-1.01656 * \text { Curcuminoids }-1.43292 * \text { Polxamer } 407
$$

Table Appendix D-21. Design-Expert® output for fitting a regression model to the nanoparticles recovery of formulation number 31 to 45

Response: Nanoparticles recovery
Sequential Model Sum of Squares


| Model Summary Statistics |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
|  | Std. |  | Adjusted | Predicted |  |
| Source | Dev. | R-Squared | R-Squared | R-Squared | PRESS |
| Linear | 1.85 | 0.3255 | 0.1415 | -0.3583 | 76.22 |
| 2FI | 1.96 | 0.4519 | 0.0409 | -1.5562 | 143.44 |
| Quadratic | 2.43 | 0.4743 | -0.4718 | -6.3639 | 413.21 |
| Cubic | 1.46 | 0.9239 | 0.4672 | STY | + |
| + Case(s) with leverage of 1.0000: PRESS statistic not defined |  |  |  |  |  |

Table Appendix D-22. Design-Expert® output of ANOVA for the reduced model of correlation between formulation ingredients and the nanoparticles recovery of formulation number 31 to 45

Response: Nanoparticles recovery
Backward Elimination Regression with Alpha to Exit $=0.050$
Forced Terms Intercept

| Removed | Coefficient <br> Estimate | $\mathbf{t}$ for $\mathbf{H 0}$ <br> Coeff $=\mathbf{0}$ | Prob $>\|\mathbf{t}\|$ | R-Squared | MSE |
| :---: | :---: | :---: | :---: | :---: | :---: |
| AB | 0.057 | 0.047 | 0.9641 | 0.4741 | 4.92 |
| $\mathrm{~A}^{2}$ | -0.060 | -0.052 | 0.9600 | 0.4739 | 4.22 |
| $\mathrm{C}^{2}$ | -0.22 | -0.20 | 0.8453 | 0.4708 | 3.71 |
| AC | 0.27 | 0.28 | 0.7845 | 0.4655 | 3.33 |
| $\mathrm{~B}^{2}$ | -0.54 | -0.57 | 0.5848 | 0.4464 | 3.11 |
| C | -0.83 | -1.32 | 0.2150 | 0.3494 | 3.32 |
| B | 0.88 | 1.37 | 0.1980 | 0.2383 | 3.56 |
| A | 0.91 | 1.36 | 0.1988 | 0.1209 | 3.79 |
| BC | 1.30 | 1.34 | 0.2040 | -0.0000 | 4.01 |

ANOVA for Response Surface Mean Model
Analysis of variance table [Partial sum of squares]
\(\left.$$
\begin{array}{rrrrrr}\text { Source } & \begin{array}{r}\text { Sum of } \\
\text { Squares }\end{array}
$$ \& DF \& \begin{array}{c}Mean <br>

Model\end{array} \& 0.000 \& 0\end{array}\right)\)| Fquare |
| :---: |
| Residual |

## Final Equation in Terms of Coded Factors:

$$
\text { Recovery }=+52.57
$$

## Final Equation in Terms of Actual Factors:

```
Recovery = +52.56733
```

Table Appendix D-23. Design-Expert ${ }^{\circledR}$ output for fitting a regression model to the particle size of formulation number 31 to 45


Table Appendix D-24. Design-Expert® output of ANOVA for the reduced model of correlation between formulation ingredients and the particle size of formulation number 31 to 45


Final Equation in Terms of Coded Factors:

```
Particle size = +382.60+23.37*A +17.50* C
```


## Final Equation in Terms of Actual Factors:

$$
\text { Particle size }=\quad+303.78750+11.68750 * \text { PLA:PGA ratio }+8.75000 * \text { PVA }
$$

Table Appendix D-25. Design-Expert ${ }^{\circledR}$ output for fitting a regression model to the polydispersity index of formulation number 31 to 45


Table Appendix D-26. Design-Expert ${ }^{\circledR}$ output of ANOVA for the reduced model of correlation between formulation ingredients and the polydispersity index of formulation number 31 to 45

## Response: Polydispersity index

Backward Elimination Regression with Alpha to Exit $=0.050$
Forced Terms Intercept

|  | Coefficient <br> Removed | $\mathbf{t}$ for $\mathbf{H} \mathbf{0}$ <br> Coeff $=\mathbf{0}$ | Prob $>\|\mathbf{t}\|$ | R-Squared | MSE |
| ---: | :---: | :---: | :---: | :---: | :---: |
| B | $2.500 \mathrm{E}-003$ | 0.14 | 0.8945 | 0.4900 | $2.150 \mathrm{E}-003$ |
| $\mathrm{~A}^{2}$ | $-3.750 \mathrm{E}-003$ | -0.16 | 0.8816 | 0.4879 | $1.850 \mathrm{E}-003$ |
| BC | $-7.500 \mathrm{E}-003$ | -0.35 | 0.7376 | 0.4790 | $1.647 \mathrm{E}-003$ |
| AB | $7.500 \mathrm{E}-003$ | 0.37 | 0.7213 | 0.4701 | $1.489 \mathrm{E}-003$ |
| C | -0.010 | -0.73 | 0.4822 | 0.4385 | $1.420 \mathrm{E}-003$ |
| AC | -0.018 | -0.93 | 0.3749 | 0.3901 | $1.402 \mathrm{E}-003$ |
| $\mathrm{~B}^{2}$ | -0.023 | -1.21 | 0.2526 | 0.3092 | $1.456 \mathrm{E}-003$ |
| $\mathrm{C}^{2}$ | -0.032 | -1.61 | 0.1335 | 0.1601 | $1.634 \mathrm{E}-003$ |
| A | 0.022 | 1.57 | 0.1394 | 0.0000 | $1.807 \mathrm{E}-003$ |

ANOVA for Response Surface Mean Model
Analysis of variance table [Partial sum of squares]
\(\left.$$
\begin{array}{rrrrrr}\text { Source } & \begin{array}{r}\text { Sum of } \\
\text { Squares }\end{array}
$$ \& DF \& \begin{array}{r}Mean <br>

Model\end{array} \& 0.000 \& 0\end{array}\right)\)| Fquare |
| ---: |
| Residual |


| Std. Dev. | 0.043 |  | R-Squared | 0.00 |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Mean | 0.93 |  | Adj R-Squared | 0.00 |  |
| C.V. | 4.58 |  | Pred R-Squared | -0.14 |  |
| PRESS | 0.029 |  | Adeq Precision |  |  |
|  | Coefficient |  | Standard | 95\% CI | 95\% CI |
| Factor | Estimate | DF | Error | Low | High |
| Intercept | 0.93 | 1 | 0.0110 .90 | 0.95 |  |

Final Equation in Terms of Coded Factors:

$$
\text { Polydispersity index }=+0.93
$$

Final Equation in Terms of Actual Factors:

$$
\text { Polydispersity index }=+0.92733
$$

Table Appendix D-27. Design-Expert ${ }^{\circledR}$ output for fitting a regression model to the curcuminoids contents of $f$ ormulation number 31 to 45

| Response: | Curcuminoids Content |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
| *** WARNING: The Cubic Model is Aliased! *** |  |  |  |  |  |
| Sequential Model Sum of Squares |  |  |  |  |  |
| Source | Sum of Squares |  | Mean | F | Prob $>$ F |
|  |  | DF | Square | Value |  |
| Mean | 120.52 | 1 | 120.52 |  |  |
| Linear | 23.88 | 3 | 7.96 | 128.41 | $<0.0001$ |
| 2FI | 0.092 | 3 | 0.031 | 0.42 | 0.7461 |
| Quadratic | 0.47 | 3 | J 0.16 | 6.74 | 0.0330 |
| Cubic | 0.066 | 3 | 0.022 | 0.86 | 0.5785 |
| Residual | 0.051 | $1-2$ | 0.026 |  |  |
| Total | 145.08 | -15 | 9.67 |  |  |
| Lack of Fit Tests |  |  |  |  |  |
| Sum of |  |  | Mean | F |  |
| Source | Squares | DF | Square | Value | Prob $>$ F |
| Linear | 0.63 | 9 | \% 0.070 | 2.74 | 0.2961 |
| 2FI | 0.54 |  | 0.090 | 3.51 | 0.2384 |
| Quadratic | $0.066$ | 3 | Cobe 0.02 | 0.86 | 0.5785 |
| Cubic | 0.000 |  |  |  |  |
| Pure Error | $0.051 \quad 20.026$ |  |  |  |  |
| Model Summary Statistics |  |  |  |  |  |
|  | Std. |  | Adjusted | Predicted | PRESS |
| Source | Dev. R | R-Squared $\cap$ R-Squared |  | R-Squared |  |
| Linear | 0.25 | 0.9722 | 09647 | 0.9502 | 1.22 |
| 2 FI | 0.27 | 0.9760 | 0.9580 | 0.9128 | 2.14 |
| Quadratic | 0.15 | 0.9952 | 0.9867 | 0.9525 | 1.17 |
| Cubic | 0.16 | 0.9979 | 0.9854 |  | + |
| + Case(s) with leverage of 1.0000: PRESS statistic not defined |  |  |  |  |  |

Table Appendix D-28. Design-Expert ${ }^{\circledR}$ output of ANOVA for the reduced model of correlation between formulation ingredients and the curcuminoids content of formulation number 31 to 45

## Response: Curcuminoids content

Backward Elimination Regression with Alpha to Exit $=0.050$
Forced Terms Intercept

| Removed | Coefficient <br> Estimate | $\mathbf{t}$ for $\mathbf{H 0}$ <br> Coeff $=\mathbf{0}$ | Prob $>\|\mathbf{t}\|$ | R-Squared | MSE |
| :---: | :---: | :---: | :---: | :---: | :---: |
| C | 0.076 | 0.89 | 0.3916 | 0.9702 | 0.061 |
| A | 0.12 | 1.42 | 0.1809 | 0.9652 | 0.066 |

ANOVA for Response Surface Reduced Quadratic Model Analysis of variance table [Partial sum of squares]

|  | Sum of |  | Mean | F |  |
| ---: | :---: | :---: | :---: | :---: | :---: |
| Source | Squares | DF | Square | Value | Prob $>$ F |
| Model | 23.70 | 1 | 23.70 | 360.34 | $<0.0001$ |
| B | 23.70 | 1 | 23.70 | 360.84 | $<0.0001$ |
| Residual | 0.85 | 13 | 0.066 |  |  |
| Lack of Fit | 0.80 | 11 | 0.073 | 2.85 | 0.2881 |
| Pure Error | 0.051 | 2 | 0.026 |  |  |
| Cor Total | 24.56 | 14 |  |  |  |


|  |  |  |  |
| :--- | :--- | :--- | :--- |
| Std. Dev. | 0.26 | R-Squared | 0.9652 |
| Mean | 2.83 | Adj R-Squared | 0.9626 |
| C.V. | 9.04 | Pred R-Squared | 0.9546 |
| PRESS | 1.11 | Adeq Precision | 36.785 |


|  | Coefficient <br> Estimate | DF | Standard <br> Error | 95\% CI <br> Low | 95\% CI <br> High | VIF |
| :--- | :---: | :---: | :---: | :---: | :---: | :---: |
| Factor |  |  |  |  |  |  |
| Intercept | 2.83 | 1 | 0.066 | 2.69 | 2.98 |  |
| B-Curcuminoids | 1.72 | i | 0.091 | 1.53 | 1.92 | 1.00 |

## Final Equation in Terms of Coded Factors:

$$
\text { Curcuminoids Content }=+2.83+1.72 * \mathrm{~B}
$$

## Final Equation in Terms of Actual Factors:

$$
\text { Curcuminoids Content }=+0.25250+0.43034 * \text { Curcuminoids }
$$

Table Appendix D-29. Design-Expert ${ }^{\circledR}$ output for fitting a regression model to the entrapment of formulation number 31 to 45


Table Appendix D-30. Design-Expert ${ }^{\circledR}$ output of ANOVA for the reduced model of correlation between formulation ingredients and the entrapment efficiency of formulation number 31 to 45

## Response: Entrapment Efficiency

Backward Elimination Regression with Alpha to Exit $=0.050$
Forced Terms Intercept

| Removed |  | Coefficient <br> Estimate | $\mathbf{t}$ for $\mathbf{H 0}$ <br> Coeff $=\mathbf{0}$ | Prob $>\|\mathbf{t}\|$ | R-Squared | MSE |
| ---: | :---: | :---: | :---: | :---: | :---: | :---: |
| C | 0.076 | 0.16 | 0.8798 | 0.9247 | 1.54 |  |
| AB | 0.12 | 0.20 | 0.8499 | 0.9242 | 1.33 |  |
| $\mathrm{C}^{2}$ | 0.57 | 0.95 | 0.3747 | 0.9144 | 1.31 |  |
| AC | 0.89 | 1.56 | 0.1585 | 0.8886 | 1.52 |  |
| BC | 1.25 | 2.03 | 0.0734 | 0.8377 | 1.99 |  |

ANOVA for Response Surface Reduced Quadratic Model
Analysis of variance table [Partial sum of squares]


|  | Coefficient <br> Estimate | DF | Standard | Error | 95\% CI | Low |
| :--- | ---: | ---: | ---: | ---: | ---: | ---: |

## Final Equation in Terms of Coded Factors:

$$
\text { Entrapment Efficiency }=+23.16+1.49 * \mathrm{~A}-2.23 * \mathrm{~B}+3.13 * \mathrm{~A}^{2}+1.73 * \mathrm{~B}^{2}
$$

## Final Equation in Terms of Actual Factors:

 Entrapment Efficiency $=+35.21010-3.94755$ * PLA:PGA ratio-1.85721 * Curcuminoids$$
+0.78240 * \text { PLA:PGA ratio }{ }^{2}+0.10826 * \text { Curcuminoids }^{2}
$$

## BIOGRAPHY

Miss Praewpun Boonyasirisri was born on October 22, 1974 in Bangkok, Thailanad. She received her Bachelor Degree of Science in Pharmacy from the Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok in 1998. Since graduation, she have been worked as a production planner in the Production Department of the Government of Pharmaceutical Organization (GPO), Bangkok. In 2002, she got a scholarship from GPO for graduate study in Pharmaceutical Technology (International Program), Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok. In 2003, she got a Grant for research publication, provided by the Ministry of University Affairs (or the Commission on Higher Education, Ministry of Education at present), Thailand, from the Graduate School of Chulalongkorn University.

